Sucampo Pharmaceuticals (SCMP) Earns Daily News Sentiment Score of 0.15
News stories about Sucampo Pharmaceuticals (NASDAQ:SCMP) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sucampo Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.2390543034897 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- $0.34 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter (americanbankingnews.com)
- Sucampo Pharmaceuticals, Inc. (SCMP) Wondering to Grab Passive Attentions on Strong Long-Term Obligations – Stock News Stop (stockmarketstop.com)
- Peter A. Kiener Sells 50,000 Shares of Sucampo Pharmaceuticals, Inc. (SCMP) Stock (americanbankingnews.com)
- Sucampo Pharmaceuticals (SCMP) Raised to “Buy” at BidaskClub (americanbankingnews.com)
- ValuEngine Upgrades Sucampo Pharmaceuticals (SCMP) to “Strong-Buy” (americanbankingnews.com)
SCMP has been the topic of several recent analyst reports. initiated coverage on shares of Sucampo Pharmaceuticals in a research note on Wednesday, November 15th. They set a “buy” rating and a $14.00 price objective on the stock. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. UBS lowered their price objective on shares of Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, October 12th. Mizuho restated a “hold” rating and set a $12.00 price objective on shares of Sucampo Pharmaceuticals in a research note on Wednesday, November 1st. Finally, Maxim Group reaffirmed a “buy” rating and set a $23.00 target price on shares of Sucampo Pharmaceuticals in a report on Thursday, November 2nd. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $16.60.
Shares of Sucampo Pharmaceuticals (SCMP) opened at $16.50 on Thursday. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The stock has a market cap of $766.01, a PE ratio of 11.13, a price-to-earnings-growth ratio of 4.84 and a beta of 1.47. Sucampo Pharmaceuticals has a twelve month low of $9.30 and a twelve month high of $17.70.
Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.25 by $0.02. The firm had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.30 EPS. equities research analysts expect that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current fiscal year.
In other news, insider Peter A. Kiener sold 50,000 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $16.50, for a total value of $825,000.00. Following the completion of the transaction, the insider now directly owns 52,023 shares in the company, valued at approximately $858,379.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.13% of the stock is currently owned by insiders.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.